TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00367406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma 3 nail versus ACE trochanteric nail
Description: Comparing Gamma 3 nail versus ACE trochanteric nail
Study: NCT03441542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-assisted Case Navigation
Description: The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
Study: NCT02918565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Cognition Feedback (DCF)
Description: 12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Risk Feedback (ARF)
Description: 12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goal Support (AGS)
Description: 12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMBO
Description: 12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
Study: NCT02921724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TreC-Onco
Description: TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~1. Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~2. Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher.
Study: NCT01168778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Workshop
Description: Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
Study: NCT01788527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Real Time Continuous Glucose Monitoring
Study: NCT05057598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based participatory research on diet and lifestyle
Description: The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information.~The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week.
Study: NCT03038867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
Study: NCT02619084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STN DBS
Description: Bilateral STN DBS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STN DBS
Description: Bilateral STN DBS
Study: NCT01852149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPAS Implant
Description: The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
Study: NCT01057147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide 2% ophthalmic suspension
Description: Instill one drop in each eye four times daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Instill one drop in each eye four times daily for 12 weeks.
Study: NCT01208142

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care treatment
Description: weekly standardized physical therapy and daily wear of an AFO

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Flexion Dynasplint
Description: Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
Study: NCT01724970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal
Description: Patients will be ventilated with PLMA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme LMA
Description: Patients will be ventilated with SLMA
Study: NCT02861586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK low dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK low dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK low dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK low dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK high dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK high dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
Study: NCT01019876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse Anti-thymocyte Globulin
Study: NCT03298451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Regimen 1)
Description: Tremelimumab IV (intravenous infusion).
Study: NCT02786498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study: NCT02861586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
Study: NCT04538534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
Study: NCT05194813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua alvim CM, neodent implant (Test)
Description: Acqua, Hydrophilic sandblasted, and acid-etched dental implants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoporous alvim CM, neodent implant (Control)
Description: Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
Study: NCT04036773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable deliveries
Description: Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
Study: NCT03298451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Regimen 2)
Description: Tremelimumab IV (intravenous infusion).
Study: NCT02861586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo
Study: NCT03298451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Regimen 1)
Description: Durvalumab IV (intravenous infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Regimen 2)
Description: Durvalumab IV (intravenous infusion).
Study: NCT03860857

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
Study: NCT02786498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03860857

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240
Study: NCT02786498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02397200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water), without added vitamins and minerals
Study: NCT01968109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986213
Description: Relatlimab + Nivolumab
Study: NCT04137263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOSE formulation
Description: over-the-counter topical
Study: NCT05261113

Intervention type: PROCEDURE
Intervention: CE-IOUS
Description: Use of contrast-enhanced intraoperative ultrasound during liver surgery
Study: NCT03500770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator
Description: The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
Study: NCT01147120

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Massage Therapy (CMT)
Description: PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
Study: NCT01100684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: 0.5 mg Asimadoline BID
Study: NCT03860857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240
Study: NCT02861586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo
Study: NCT01100684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03414164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidine
Description: natural antioxidants
Study: NCT02861586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo
Study: NCT01174706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information prescriptions
Description: One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information prescriptions
Description: One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information prescriptions
Description: One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information prescriptions
Description: One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.